Efficacy of asexual blood-stage antigens and antigen combinations for vaccination of mice against Plasmodium chabaudi.
无性血期抗原和抗原组合对小鼠接种恰鲍迪疟原虫疫苗的功效。
基本信息
- 批准号:nhmrc : 191210
- 负责人:
- 金额:$ 19.09万
- 依托单位:
- 依托单位国家:澳大利亚
- 项目类别:NHMRC Project Grants
- 财政年份:2002
- 资助国家:澳大利亚
- 起止时间:2002-01-01 至 2004-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The development of a vaccine against malaria is one of the world's major public health priorities. Over the last two decades much progress has been made towards the development of a malaria vaccine but none is yet available that is suitable for use in humans. Many parasite molecules have been identified that are considered potential components of a malaria vaccine and some of these have already reach the stage of being tested in early clinical trials. However, a major problem confronting the field of malaria vaccine development is finding the resources necessary to test the large number of antigens and antigen combinations that are considered of potential value. One way to gain information that will help to determine which antigens and antigen combinations should have priority for testing in clinical trials is to carry out vaccine trials in monkeys or mice using malaria parasites that infect these species. We will use Plasmodium chabaudi infections in the mouse to examine the ability of three antigens from the disease causing blood stages of the parasite to induce antibody responses that prevent the development of severe malaria. We will determine whether antigen combinations provide better protection than single antigens when mice are challenged with a variety of parasite strains. Detailed analyses of the antibody responses will be carried out to determine if combining antigens changes the response in a way that may help or hinder vaccine efficacy.
研制疟疾疫苗是世界上主要的公共卫生优先事项之一。在过去的二十年里,疟疾疫苗的开发取得了很大进展,但还没有适合人类使用的疫苗。许多寄生虫分子已被确定为疟疾疫苗的潜在成分,其中一些已经达到了在早期临床试验中进行测试的阶段。然而,疟疾疫苗开发领域面临的一个主要问题是找到测试被认为具有潜在价值的大量抗原和抗原组合所需的资源。获得有助于确定哪些抗原和抗原组合应优先用于临床试验的信息的一种方法是在猴子或小鼠中使用感染这些物种的疟疾寄生虫进行疫苗试验。我们将使用疟原虫chabaudi感染的小鼠,以检查三种抗原的能力,从疾病引起的寄生虫的血液阶段,以诱导抗体反应,防止严重疟疾的发展。我们将确定抗原组合是否比单一抗原提供更好的保护,当小鼠受到各种寄生虫菌株的挑战。将对抗体应答进行详细分析,以确定结合抗原是否以可能有助于或阻碍疫苗效力的方式改变应答。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robin Anders其他文献
Robin Anders的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Impact of infection complexity on P. falciparum sexual commitment and gametocytemia
感染复杂性对恶性疟原虫性承诺和配子体血症的影响
- 批准号:
10681571 - 财政年份:2023
- 资助金额:
$ 19.09万 - 项目类别:
Discovering resistance-resistant antimalarial drug target
发现耐药性抗疟药物靶点
- 批准号:
10741535 - 财政年份:2023
- 资助金额:
$ 19.09万 - 项目类别:
Malaria parasite harbors a unique protein lysine methyltransferase targeting both chromatin and motility machinery
疟原虫具有独特的蛋白质赖氨酸甲基转移酶,针对染色质和运动机制
- 批准号:
10741300 - 财政年份:2023
- 资助金额:
$ 19.09万 - 项目类别:
Cofactor metabolism and mitochondrial function in malaria parasites
疟原虫的辅因子代谢和线粒体功能
- 批准号:
10659968 - 财政年份:2023
- 资助金额:
$ 19.09万 - 项目类别:
Functional characterization of striated fiber assemblins in malaria parasites
疟疾寄生虫中横纹纤维组装体的功能特征
- 批准号:
10675782 - 财政年份:2023
- 资助金额:
$ 19.09万 - 项目类别:
Developing a new chordate model for stem cell biology and regeneration
开发用于干细胞生物学和再生的新脊索动物模型
- 批准号:
10373777 - 财政年份:2022
- 资助金额:
$ 19.09万 - 项目类别:
Plasmodium Protein Kinase Focused Antimalarials Discovery
疟原虫蛋白激酶聚焦抗疟药的发现
- 批准号:
10533634 - 财政年份:2022
- 资助金额:
$ 19.09万 - 项目类别:
Focal mass drug administration (fMDA) to reduce Plasmodium vivax transmission, a pragmatic cluster randomized controlled trial in Peru
旨在减少间日疟原虫传播的集中集中药物管理(fMDA),这是秘鲁的一项实用整群随机对照试验
- 批准号:
10488139 - 财政年份:2022
- 资助金额:
$ 19.09万 - 项目类别:
Evaluating host-directed therapeutics against blood-stage malaria parasites
评估针对血期疟疾寄生虫的宿主导向疗法
- 批准号:
10665779 - 财政年份:2022
- 资助金额:
$ 19.09万 - 项目类别:
Developing a new chordate model for stem cell biology and regeneration
开发用于干细胞生物学和再生的新脊索动物模型
- 批准号:
10580589 - 财政年份:2022
- 资助金额:
$ 19.09万 - 项目类别: